Atypical cutaneous leishmaniasis in two patients receiving low-dose methotrexate

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 830-833

  Saha, M ^a   Shipley, D ^b   McBride, S ^a   Kennedy, C ^b   Vega Lopez, F ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Cutaneous leishmaniasis; Immunosuppression; Methotrexate

Indexed keywords

METHOTREXATE; STIBOGLUCONATE SODIUM;

ADULT; AGED; AGGLUTINATION TEST; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LEISHMANIASIS; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGED; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LEISHMANIASIS, CUTANEOUS; MALE; METHOTREXATE; OPPORTUNISTIC INFECTIONS;

EID: 33748466167     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07418.x     Document Type: Article

References (21)

1. Herwaldt B, Berman J. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296-306.
2. Venenice P, Bouree P, Hiesse C, Viellefond A. Disseminated cutaneous leishmaniasis in a case of an immunodepressed woman. Ann Dermatol Venereol 1993; 120:461-3.
3. Castellino G, Govoni M, Lo Monaco A et al. Visceral leishmaniasis complicating a connective tissue disease: three case reports from Italy. Lupus 2004; 13:201-3.
4. Vardy DA, Cohen A, Kachko L. Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous nodule. Br J Dermatol 1999; 141:914-17.
5. Couppie P, Clyti E, Sobesky M et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165-71.
6. Vega-Lopez F. Diagnosis of cutaneous leishmaniasis. Curr Opin Infect Dis 2003; 16:97-101.
7. Schallig HD, Oskam L. Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Trop Med Int Health 2002; 7:641-51.
8. Reed SG, Scott P. T-cell and the cytokine responses in leishmaniasis. Curr Opin Immunol 1993; 5:524-31.
9. Lehmann J, Enssle KH, Lehmann I et al. The capacity to produce IFN gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20:63-77.
10. Viana da Costa A, Huerre M, Delacre M et al. IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int 2002; 51:367-79.
11. Himmelrich H, Launois P, Maillard I, Biedermann T. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 2000; 164:4819-25.
12. Etges R, Muller I. Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions. J Mol Med 1998; 76:372-90.
13. Jones D, Elloso M, Scott P. Host susceptibility factors to cutaneous leishmaniasis. Front Biosci 1998; 15:D1171-80.
14. Scott P. Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol Res 2003; 27:489-98.
15. Afonsono L, Scharton T, Viera L, Wysocka M. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263:235-7.
16. Kemp M, Kurtzhals JA, Bendtzen K et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 1993; 61:1069-73.
17. Smolen JS, Tohidast-Akrad M, Gal A. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol 1996; 25:1-4.
18. Constantin A, Loubet-Lescoulie P, Lambert N et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcription-polymerase chain reaction. Arthritis Rheum 1998; 41:48-57.
19. Hessian P, Highton J, Kean A, Sun CK. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 2003; 48:334-8.
20. Gerards AH, de Lathouder S, de Groot ER et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:1189-96.
21. Neurath MF, Hildner K, Becker C et al. Methotrexate specifically modulates cytokine production by cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999; 115:42-55.